The sources said the Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September.
Week after launching drive, Delhi runs out of Covaxin stock for 18-44
By IANS |
8 Views
Week after launching drive, Delhi runs out of Covaxin stock for 18-44. Image Source: IANS News
New Delhi, May 12 : A week after kick-starting the Covid vaccination drive for those in the age group of 18-44 years, the national capital has ran out of its Covaxin stock for this particular segment.
The Delhi government, which had recently said that it would vaccinate all the citizens of the national capital in the next three months, said on Wednesday that Covaxin stock is completely finished at all its centers.
Amid multiple states reporting a shortage of COVID-19 vaccine, Serum Institute and Bharat Biotech have submitted to the Centre their production plan for the next four months, informing they can ramp it up to 10 crore and 7.8 crore doses respectively by August, official sources said on Wednesday The sources said the Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September. The Hyderabad-based Bharat Biotech s indigenously developed Covaxin and Oxford-AstraZeneca s Covishield, being manufactured by the Pune-based Serum Institute of India, are currently being used in India s inoculation drive against coronavirus.
Bharat Biotech s Covaxin recommended by expert panel for phase 2/3 trials on 2-18 year-olds yourstory.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yourstory.com Daily Mail and Mail on Sunday newspapers.